Also trades as: 0A8E.L (LSE) · $vol 0M
XERS NASDAQ
Xeris Biopharma Holdings, Inc.
1W: -6.8%
1M: +12.2%
3M: +23.9%
YTD: +38.9%
1Y: +11.8%
3Y: +490.2%
5Y: +446.0%
$10.45
+0.24 (+2.35%)
After Hours: $10.38 (-0.07, -0.72%)
Weekly Expected Move ±9.7%
$8
$9
$10
$11
$12
Credit Risk of going bust: higher than 53% of companies Debt: 13.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.19 (down 98%), Xeris Biopharma Holdings, Inc. would be worth roughly what it owes.
Total debt $289.4M against a stock market value of $1.86B.
Distance to default 4.87 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $158.2M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' -4.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.19 (down 98%), Xeris Biopharma Holdings, Inc. would be worth roughly what it owes.
Total debt $289.4M against a stock market value of $1.86B.
Distance to default 4.87 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $158.2M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' -4.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (78)
Oppenheimer's top 50 small- and mid-cap Buy list
Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call - Benzinga
Insider Sell Alert: Beth Hecht Sells 16,666 Shares of Xeris Biop - GuruFocus
Insider Steven Pieper Sells 5,000 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
An officer plans a $159K share sale at Xeris Biopharma (XERS). - Stock Titan
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
Xeris Biopharma (XERS) Stock Jumps 6% Amid Acquisition Interest from Lundbeck - GuruFocus
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’ - Yahoo Finance
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
Xeris Biopharma jumps on report of interest from H Lundbeck
A Xeris Biopharma (XERS) officer proposes a share sale valued at $637,000. - Stock Titan
Corient Private Wealth LP Acquires 184,126 Shares of Xeris Biopharma Holdings, Inc. $XERS
WINTON GROUP Ltd Reduces Stock Position in Xeris Biopharma Holdings, Inc. $XERS
Xeris Biopharma Holdings (NasdaqGS:XERS) Stock Forecast & Analyst Predictions - Simply Wall Street
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Bank of New York Mellon Corp Invests $3.87 Million in Xeris Biopharma Holdings, Inc. $XERS
Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdings, Inc. $XERS
Bank of America Corp DE Increases Stake in Xeris Biopharma Holdings, Inc. $XERS
Xeris Announces Details for XP-8121 Program Overview Webinar
Xeris will outline its once-weekly injection for hypothyroidism on Sept. 9 - Stock Titan
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Simply Wall Street
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues - Simply Wall Street
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain?
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
Xeris (XERS) Q2 2026 Earnings Call Transcript
Xeris (XERS) Q2 2026 Earnings Call Transcript
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses - Simply Wall Street
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
Xeris Biopharma Reports Second Quarter 2026 Financial Results
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last? - Yahoo Finance
Insider Sale: See Remarks of $XERS Sells 17,400 Shares - Quiver Quantitative
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
Xeris Announces Updates to Its Board of Directors
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity? - Yahoo Finance
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Xeris (XERS) Q1 2026 Earnings Call Transcript
Xeris forecasts $380M-$390M 2026 revenue as Recorlev commercial expansion ramps in H2
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Pharmaceuticals GAAP EPS of $0.01 beats by $0.02, revenue of $82M beats by $2.01M
Xeris Pharmaceuticals Q1 2026 Earnings Preview
Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed | XERS Stock News - Quiver Quantitative
Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS
Xeris rises on 2026 revenue guidance, Q4 top-line beat
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Xeris Biopharma Holdings Q4 Earnings Assessment
Xeris Pharmaceuticals GAAP EPS of $0.06 beats by $0.03, revenue of $85.81M misses by $0.19M
Earnings Scheduled For March 2, 2026
Here are the major earnings before the open Monday
Xeris Pharmaceuticals Q4 2025 Earnings Preview
Why Are Shares Of Xeris Biopharma Falling Friday?
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares of Stock
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma (NASDAQ:XERS) Shares Gap Up – What’s Next?
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Xeris Biopharma (NASDAQ:XERS)
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Analysts